Ask your pharmacist or other health care provider if you are unsure how to use Dupixent. If you miss a dose of this medicine, you should use the missed dose as soon as you remember if it has ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report third-quarter results on Oct. 31, 2024. The Zacks ...

(NASDAQ: REGN) and Sanofi (NASDAQ:SNY) have reported positive outcomes from a Phase 3 trial of Dupixent (dupilumab ... allowing for significantly longer dosing intervals. These are some of ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) to reduce COPD exacerbations in some patients whose symptoms aren’t adequately controlled with inhaled medicines.

Oct. 2, 2024 — The FDA has approved Regeneron and Sanofi’s drug Dupixent for patients with COPD (chronic obstructive pulmonary disease). Marking the sixth indication for the drug, the approval ...

Ebglyss has similar efficacy and safety to Dupixent, but with one key advantage: the convenience of maintenance dosing every four weeks versus every two weeks for Dupixent. That will probably not ...

However, Drontal can be found over the counter and has a dosing chart listed on the back of the product. Drontal can only be ...

The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease ...

Sanofi SNY and partner Regeneron REGN announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth indication — chronic obstructive pulmonary disease (COPD ...

Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi (SASY.PA), opens new tab and Regeneron's (REGN.O), opens new tab blockbuster drug Dupixent for patients with a chronic ...

Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status Confirmatory data to support U.S. regulatory resubmission by year-end ...

Sanofi's existing product line boasts several top-tier drugs, including immunology drug Dupixent, an IL-4/IL-13 inhibitor. Dupixent looks well positioned to reach peak sales of over EUR 18 billion ...